Trials / Recruiting
RecruitingNCT05800665
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
A Phase 1, Open-Label, Multicenter, Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 in Patients With Advanced or Metastatic Prostate Cancer
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 210 (estimated)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of RO7656594 in participants with advanced or metastatic prostate cancer. It will also identify recommended doses and regimens for RO7656594 for subsequent studies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RO7656594 | RO7656594 will be administered orally at specified dose on specified days. |
Timeline
- Start date
- 2023-05-02
- Primary completion
- 2027-06-30
- Completion
- 2027-06-30
- First posted
- 2023-04-05
- Last updated
- 2026-03-19
Locations
25 sites across 7 countries: United States, Australia, Canada, France, South Korea, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05800665. Inclusion in this directory is not an endorsement.